DT-168
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fuchs Endothelial Corneal Dystrophy
Conditions
Fuchs Endothelial Corneal Dystrophy, Fuchs
Trial Timeline
Jul 30, 2025 → Dec 1, 2026
NCT ID
NCT07024693About DT-168
DT-168 is a phase 2 stage product being developed by Design Therapeutics for Fuchs Endothelial Corneal Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07024693. Target conditions include Fuchs Endothelial Corneal Dystrophy, Fuchs.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07024693 | Phase 2 | Recruiting |
Competing Products
1 competing product in Fuchs Endothelial Corneal Dystrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| QR-504a | ProQR | Phase 1 | 25 |